Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma.

de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, Ferman SE, Lucena E, Lopez-Camelo JS, Seuánez HN, Vargas FR.

Pediatr Blood Cancer. 2012 Jul 15;59(1):39-43. doi: 10.1002/pbc.24014. Epub 2011 Dec 16.

PMID:
22180099
2.

Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.

Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI.

PLoS One. 2010 May 26;5(5):e10813. doi: 10.1371/journal.pone.0010813.

3.

Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma.

McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, Zhang J, Dyer MA.

PLoS One. 2012;7(8):e42739. doi: 10.1371/journal.pone.0042739. Epub 2012 Aug 20.

4.

Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

Guo Y, Pajovic S, Gallie BL.

Biochem Biophys Res Commun. 2008 Oct 10;375(1):1-5. doi: 10.1016/j.bbrc.2008.07.055. Epub 2008 Jul 21.

5.

MDM2 as a modifier gene in retinoblastoma.

Castéra L, Sabbagh A, Dehainault C, Michaux D, Mansuet-Lupo A, Patillon B, Lamar E, Aerts I, Lumbroso-Le Rouic L, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C.

J Natl Cancer Inst. 2010 Dec 1;102(23):1805-8. doi: 10.1093/jnci/djq416. Epub 2010 Nov 4.

6.

Distinct roles of Mdm2 and Mdm4 in red cell production.

Maetens M, Doumont G, Clercq SD, Francoz S, Froment P, Bellefroid E, Klingmuller U, Lozano G, Marine JC.

Blood. 2007 Mar 15;109(6):2630-3. Epub 2006 Nov 14.

7.

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.

Perfumo C, Parodi S, Mazzocco K, Defferrari R, Inga A, Scarrà GB, Ghiorzo P, Haupt R, Tonini GP, Fronza G.

Pediatr Blood Cancer. 2009 Oct;53(4):576-83. doi: 10.1002/pbc.22132.

PMID:
19526525
8.

The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.

Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW, Lopez-Garcia MA, Green AR, Reis-Filho JS, Ellis IO.

J Pathol. 2010 Mar;220(4):419-34. doi: 10.1002/path.2663.

PMID:
20044801
9.

Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.

Steinman HA, Hoover KM, Keeler ML, Sands AT, Jones SN.

Oncogene. 2005 Nov 24;24(53):7935-40.

PMID:
16027727
10.

Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G.

Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31. Epub 2006 Feb 21.

11.

Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4.

Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G.

Mol Cell Biol. 2006 Jan;26(1):192-8.

12.

Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.

Suda T, Yoshihara M, Nakamura Y, Sekiguchi H, Godai TI, Sugano N, Tsuchida K, Shiozawa M, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M, Matsukuma S, Miyagi Y.

Oncol Rep. 2011 Jul;26(1):49-54. doi: 10.3892/or.2011.1270. Epub 2011 Apr 18.

PMID:
21503588
13.

High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.

Veerakumarasivam A, Scott HE, Chin SF, Warren A, Wallard MJ, Grimmer D, Ichimura K, Caldas C, Collins VP, Neal DE, Kelly JD.

Clin Cancer Res. 2008 May 1;14(9):2527-34. doi: 10.1158/1078-0432.CCR-07-4129.

14.

Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma.

Würl P, Meye A, Berger D, Lautenschläger C, Bache M, Holzhausen HJ, Schmidt H, Dralle H, Rath FW, Taubert H.

Langenbecks Arch Surg. 1998 Mar;383(1):99-103.

PMID:
9627179
15.

Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Jacob AG, O'Brien D, Singh RK, Comiskey DF Jr, Littleton RM, Mohammad F, Gladman JT, Widmann MC, Jeyaraj SC, Bolinger C, Anderson JR, Barkauskas DA, Boris-Lawrie K, Chandler DS.

Neoplasia. 2013 Sep;15(9):1049-63.

16.

A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM.

Cancer Cell. 2006 Apr;9(4):273-85.

17.

Retinoblastoma.

Lohmann D.

Adv Exp Med Biol. 2010;685:220-7. Review.

PMID:
20687510
18.

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.

Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G.

Nat Genet. 2001 Sep;29(1):92-5.

PMID:
11528400
19.

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Palani CD, Beck JF, Sonnemann J.

Invest New Drugs. 2012 Feb;30(1):25-36. doi: 10.1007/s10637-010-9510-7. Epub 2010 Aug 3.

PMID:
20680659
20.

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.

Cattelani S, Defferrari R, Marsilio S, Bussolari R, Candini O, Corradini F, Ferrari-Amorotti G, Guerzoni C, Pecorari L, Menin C, Bertorelle R, Altavista P, McDowell HP, Boldrini R, Dominici C, Tonini GP, Raschellà G, Calabretta B.

Clin Cancer Res. 2008 Jun 1;14(11):3248-53. doi: 10.1158/1078-0432.CCR-07-4725.

Items per page

Supplemental Content

Write to the Help Desk